Zurcher Kantonalbank Zurich Cantonalbank Has $2.29 Million Holdings in UiPath Inc. (NYSE:PATH)

Zurcher Kantonalbank Zurich Cantonalbank decreased its stake in shares of UiPath Inc. (NYSE:PATH) by 2.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 92,231 shares of the healthcare company’s stock after selling 2,268 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in UiPath were worth $2,291,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of PATH. 180 Wealth Advisors LLC raised its stake in UiPath by 0.3% during the 4th quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company’s stock worth $4,497,000 after buying an additional 492 shares during the period. Bleakley Financial Group LLC increased its holdings in shares of UiPath by 4.9% during the fourth quarter. Bleakley Financial Group LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after acquiring an additional 598 shares in the last quarter. Simplicity Solutions LLC raised its position in shares of UiPath by 4.9% during the fourth quarter. Simplicity Solutions LLC now owns 12,691 shares of the healthcare company’s stock worth $315,000 after purchasing an additional 598 shares during the period. Arizona State Retirement System lifted its holdings in shares of UiPath by 0.8% in the 3rd quarter. Arizona State Retirement System now owns 97,951 shares of the healthcare company’s stock worth $1,676,000 after purchasing an additional 733 shares in the last quarter. Finally, Axxcess Wealth Management LLC grew its position in UiPath by 2.6% in the 3rd quarter. Axxcess Wealth Management LLC now owns 29,121 shares of the healthcare company’s stock valued at $498,000 after purchasing an additional 740 shares during the period. Institutional investors own 62.50% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Ashim Gupta sold 16,000 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $22.84, for a total transaction of $365,440.00. Following the completion of the transaction, the chief financial officer now directly owns 87,505 shares of the company’s stock, valued at approximately $1,998,614.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 72,000 shares of company stock valued at $1,591,360. Company insiders own 31.03% of the company’s stock.

UiPath Price Performance

PATH stock opened at $19.54 on Wednesday. The stock’s fifty day simple moving average is $22.55 and its two-hundred day simple moving average is $21.56. UiPath Inc. has a 1-year low of $12.38 and a 1-year high of $27.87.

UiPath (NYSE:PATH) last released its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.10. The company had revenue of $405.25 million for the quarter, compared to analysts’ expectations of $383.32 million. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. On average, equities research analysts forecast that UiPath Inc. will post -0.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on PATH shares. Truist Financial restated a “buy” rating and set a $32.00 price objective on shares of UiPath in a report on Wednesday, March 20th. KeyCorp began coverage on shares of UiPath in a research report on Monday, April 8th. They issued an “overweight” rating and a $27.00 price target on the stock. Mizuho boosted their price objective on UiPath from $22.00 to $25.00 and gave the stock a “neutral” rating in a report on Thursday, March 14th. Needham & Company LLC reissued a “buy” rating and issued a $30.00 price objective on shares of UiPath in a research note on Wednesday, March 20th. Finally, JPMorgan Chase & Co. raised UiPath from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $22.00 to $28.00 in a research report on Thursday, March 14th. Nine equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $27.41.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.